semaglutide for autoimmune disease GLP-1s Using GLP-1 Agonists with Biologics

Topline data from their MASH trial is expected this summer, and the alcohol liver disease trial will begin enrolling in the fall

Biochim Biophys Acta (2012) 1821(11):141524

GLP-1-induced intra-islet insulin secretion may locally inhibit glucagon secretion

The results indicated that the esterified form had enhanced bioavailability, with peak concentrations occurring between 924 h

The free fraction of semaglutide is absorbed faster into the circulation, which in turn leads to the observed higher and earlier maximum semaglutide concentration

Brenta G, Vaisman M, Sgarbi JA, Bergoglio LM, de Andrada NC, Bravo PP et al (2013) Clinical practice guidelines for the management of hypothyroidism